A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report

Journal of Clinical Lipidology

Volumn 8, Issue 4, 2014, Pages 455-459

  Schofield, Jonathan D ^a,b   Liu, Yifen ^b   France, Michael W ^a   Sandle, Lance ^c   Soran, Handrean ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c TRAFFORD GENERAL HOSPITAL   (United Kingdom)

Author keywords

Fenofibrate; High density lipoprotein; High density lipoprotein cholesterol; Paradoxical reduction in high density lipoprotein cholesterol

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; AMLODIPINE; ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; LANSOPRAZOLE; NITROFURANTOIN; PYRROLE DERIVATIVE;

ADULT; ATHEROGENESIS; CASE REPORT; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID METABOLISM; MIDDLE AGED; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; DRUG EFFECTS; DRUG INTERACTION; DYSLIPIDEMIAS; METABOLISM; TREATMENT OUTCOME;

AMLODIPINE; CHOLESTEROL, HDL; DRUG INTERACTIONS; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HEPTANOIC ACIDS; HUMANS; LANSOPRAZOLE; LIPID METABOLISM; MIDDLE AGED; NITROFURANTOIN; PYRROLES; TREATMENT OUTCOME;

EID: 84905923239     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.05.003     Document Type: Article

References (37)

1. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104:3046-3051.
2. Barter P, Kastelein J, Nunn A, Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis. 2003;168:195-211.
3. Farnier M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P. Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. Lipids Health Dis. 2011;10:212.
4. Schofield JD, France M, Ammori B, Liu Y, Soran H. High-density lipoprotein cholesterol raising: does it matter? Curr Opin Cardiol. 2013; 28:464-474.
5. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362: 1563-1574.
6. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366:1849-1861.
7. Aslibekyan S, Goodarzi MO, Frazier-Wood AC, et al. Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate. PLoS One. 2012;7:e48663.
8. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185-197.
9. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
10. Liu Y, Ordovas JM, Gao G, et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenet Genomics. 2009;19:161-169.
11. Schwing W, Hustak L, Taylor HC. Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction. Endocr Pract. 2010;16:382-388.
12. Mombelli G, Pazzucconi F, Bondioli A, et al. Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed. Cardiovasc Ther. 2010;28:153-160.
13. Magee G, Sharpe PC. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon. J Clin Pathol. 2009;62:250-253.
14. Cardot P, Chambaz J, Kardassis D, Cladaras C, Zannis VI. Factors participating in the liver-specific expression of the human apolipoprotein A-II gene and their significance for transcription. Biochemistry. 1993;32:9080-9093.
15. Hennuyer N, Poulain P, Madsen L, et al. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. Circulation. 1999;99: 2445-2451.
16. van der Hoogt CC, de Haan W, Westerterp M, et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res. 2007;48:1763-1771.
17. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1996;16: 763-772.
18. Foger B, Ritsch A, Doblinger A, Wessels H, Patsch JR. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1996;16(12):1430-1436.
19. Jeong S, Han M, Lee H, et al. Effects of fenofibrate on high-fat dietinduced body weight gain and adiposity in female C57BL/6J mice. Metabolism. 2004;53:1284-1289.
20. Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995;96:741-750.
21. Ribas V, Palomer X, Roglans N, et al. Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate. Biochim Biophys Acta. 2005;1737: 130-137.
22. Beghin L, Capps N, Duhal N, Davies J, Staels B, Luc G. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Ann Clin Biochem. 1999;36(Pt 4):523-525.
23. Franceschini G, Calabresi L, Colombo C, Favari E, Bernini F, Sirtori CR. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis. 2007;195:385-391.
24. Knopp RH, Walden CE, Warnick GR, Albers JJ, Ginsberg J, McGinnis BM. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E. Am J Med. 1987;83:75-84.
25. Sviridov D, Nestel PJ. Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol. 2007;18:157-163.
26. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412-423.
27. Ko HS, Kim CJ, Ryu WS. Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function. J Cardiovasc Pharmacol. 2005;46:405-411.
28. Staels B, van Tol A, Skretting G, Auwerx J. Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates. J Lipid Res. 1992;33(5):727-735.
29. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7: 53-58.
30. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res. 1997;38:191-205.
31. Declercq V, Yeganeh B, Moshtaghi-Kashanian GR, Khademi H, Bahadori B, Moghadasian MH. Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice. J Cardiovasc Pharmacol. 2005;46:18-24.
32. Christidis DS, Liberopoulos EN, Kakafika AI, et al. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther. 2006;11:211-221.
33. Brisson D, Ledoux K, Bosse Y, et al. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics. 2002;12:313-320.
34. Foucher C, Rattier S, Flavell DM, et al. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferatoractivated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics. 2004;14:823-829.
35. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.
36. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-1818.
37. Linz PE, Lovato LC, Byington RP, et al. Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial. Diabetes Care. 2014;37: 686-693.